Aura Biosciences, Inc. (NASDAQ:AURA)
| Market Cap | 668.20M+6.1% |
| Revenue (ttm) | 0 |
| Net Income | -131.01M-29.2% |
| EPS | -1.78+9.2% |
| Shares Out | 103.44M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 723,716 |
| Open | 6.07 |
| Previous Close | 6.17 |
| Day's Range | 6.05 - 6.56 |
| 52-Week Range | 4.73 - 9.54 |
| Beta | 0.41 |
| Analysts | Buy |
| Price Target | 17.50(+170.90%) |
| Earnings Date | Nov 12, 2026 |
Insiders here have filed 5 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About AURA
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$AURA stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in AURA holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by AURA's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
AURA Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New AURA patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to AURA from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in AURA
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $21.25M |
| IWMiShares Russell 2000 ETF | $8.90M |
| VXFVanguard Extended Market ETF | $8.13M |
| XBIState Street SPDR S&P Biotech ETF | $6.06M |
| IWOiShares Russell 2000 Growth ETF | $3.12M |
| IBBiShares Biotechnology ETF | $3.10M |
Estimated from each fund’s disclosed top holdings × AUM
AURA Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from AURA’s recent data — informational, not investment advice